Skip to Content
Looking to save on your medications?  Find out how 


Generic name: tildrakizumab systemic

Brand names: Ilumya

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Prefilled Syringe, Subcutaneous [preservative free]:

Ilumya: tildrakizumab-asmn 100 mg/mL (1 mL) [contains polysorbate 80]


Mechanism of Action

Human IgG1/k monoclonal antibody which selectively binds to the p19 subunit of interleukin (IL)-23, thereby inhibiting its interaction with the IL-23 receptor, resulting in inhibition of the proinflammatory cytokines and chemokines associated the binding of naturally occurring IL-23.



Vd: 10.8 L


Expected to be degraded into small peptides and amino acids via catabolic pathways in a similar manner as endogenous IgG.

Time to Peak

~6 days; steady state concentrations reached by week 16

Half-Life Elimination

~23 days

Use in Specific Populations

Special Populations Note

Body Weight: Tildrakizumab concentrations were lower in subjects with higher body weight.

Use: Labeled Indications

Plaque psoriasis: Treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.


Serious hypersensitivity to tildrakizumab or any component of the formulation

Dosage and Administration

Dosing: Adult

Plaque psoriasis: SubQ: 100 mg at weeks 0, 4, and then every 12 weeks thereafter.

Dosing: Geriatric

Refer to adult dosing.


Allow prefilled syringe in original carton to sit and reach room temperature (30 minutes) before injecting. Solution should be colorless to light yellow; do not use if solution has visible particles or the syringe is damaged. Syringe may contain small air bubbles; there is no need to expel air bubbles prior to administration. After injection, discard used prefilled syringe and any unused portion.


SubQ: Administer SubQ into thighs, upper arm, or abdomen (except for 2 inches around navel); do not inject into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis, or where there are scars, blood vessels, or stretch marks.


Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton. Protect from light; do not freeze. Do not shake. Can be kept at room temperature at 25°C (77°F) for up to 30 days in the original carton. Once stored at room temperature, do not place back in the refrigerator. Discard if not used within 30 days. Do not store above 25°C (77°F).

Drug Interactions

Belimumab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. Avoid combination

InFLIXimab: May enhance the immunosuppressive effect of Biologic Anti-Psoriasis Agents. Avoid combination

Vaccines (Live): Tildrakizumab may enhance the adverse/toxic effect of Vaccines (Live). The risk for contracting an infection from the vaccine may be increased. Tildrakizumab may diminish the therapeutic effect of Vaccines (Live). Avoid combination

Adverse Reactions


Infection: Infection (23%)

Respiratory: Upper respiratory tract infection (14%)

1% to 10%:

Gastrointestinal: Diarrhea (2%)

Immunologic: Antibody development (7%; neutralizing: 3%)

Local: Injection site reaction (3%)

Frequency not defined:

Dermatologic: Urticaria

Hypersensitivity: Angioedema

Respiratory: Tuberculosis

<1%, postmarketing, and/or case reports: Dizziness, limb pain, severe infection


Concerns related to adverse effects:

  • Hypersensitivity: Hypersensitivity, including anaphylaxis and angioedema, has been reported. Discontinue immediately with signs/symptoms of a serious hypersensitivity reaction and treat appropriately, as indicated.
  • Infections: May increase the risk of infections; upper respiratory tract infections have occurred more frequently. Consider the risks versus benefits prior to treatment initiation in patients with a history of chronic or recurrent infection; treatment should not be initiated in patients with clinically important active infections until it is resolved or treated. Monitor for infections; patients should seek medical attention for signs/symptoms of a clinically important infection (acute or chronic). If a serious infection develops or is unresponsive to appropriate therapy for the infection, monitor closely and consider discontinuing use until the infection resolves.

Disease-related concerns:

  • Tuberculosis: Patients should be evaluated for tuberculosis (TB) infection prior to initiating therapy. Do not administer to patients with an active TB infection. Treatment for latent TB should be administered prior to administering tildrakizumab. Consider anti-TB therapy prior to treatment initiation in patients with a history of latent or active TB in whom an adequate course of TB treatment cannot be confirmed. Monitor closely for signs/symptoms of active TB during and after treatment.

Concurrent drug therapy issues:

  • Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there are no data available concerning secondary transmission of infection by live vaccines in patients receiving therapy.

Monitoring Parameters

Latent tuberculosis screening (prior to initiating and periodically during therapy); signs and symptoms of infection, including active tuberculosis (during and after treatment).


Pregnancy Considerations

Tildrakizumab is a humanized monoclonal antibody (IgG1). Placental transfer of human IgG is dependent upon the IgG subclass, maternal serum concentrations, birth weight, and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).

Patient Education

  • Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
  • Patient may experience common cold symptoms, injection site irritation, or diarrhea. Have patient report immediately to prescriber signs of infection, coughing up blood, skin sores, sweating a lot, muscle pain, muscle weakness, shortness of breath, passing a lot of urine, abdominal pain, weight loss, severe dizziness, or passing out (HCAHPS).
  • Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Source: Wolters Kluwer Health. Last updated October 30, 2019.